A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

British Journal of Cancer
N E SchoemakerW W ten Bokkel Huinink

Abstract

The purpose of this phase II trial was to compare the efficacy, safety and pharmacokinetics of four irinotecan schedules for the treatment of metastatic colorectal cancer. In total, 174 5-fluorouracil pretreated patients were randomised to: arm A (n=41), 350 mg m(-2) irinotecan as a 90-min i.v. infusion q3 weeks; arm B (n=38), 125 mg m(-2) irinotecan as a 90-min i.v. infusion weekly x 4 weeks q6 weeks; arm C (n=46), 250 mg m(-2) irinotecan as a 90-min i.v. infusion q2 weeks; or arm D (n=49), 10 mg m(-2) day(-1) irinotecan as a 14-day continuous infusion q3 weeks. No significant differences in efficacy across the four arms were observed, although a shorter time to treatment failure was noted for arm D (1.7 months; P=0.02). Overall response rates were in the range 5-11%. Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months). Similarly, there were no significant differences in the incidence of grade 3-4 toxicities, although the toxicity profile between arms A, B, and C and D did differ. Generally, significantly less haematologic toxicity, alopecia and cholinergic syndrome were observed in arm D; however, there was a trend for increased gastro...Continue Reading

References

Dec 2, 1992·Journal of the National Cancer Institute·H A BurrisD D Von Hoff
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R OhnoM Oguro
Nov 1, 1985·Clinical Pharmacology and Therapeutics·L B Sheiner, L Z Benet
Feb 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G G ChabotR Bugat
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y ShimadaN Ogawa
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergD D Von Hoff
Sep 1, 1996·Critical Reviews in Oncology/hematology·N MasudaM Fukuoka
Sep 1, 1996·Critical Reviews in Oncology/hematology·S O'Reilly, E K Rowinsky
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P RougierM Mahjoubi
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E GuptaM J Ratain
Aug 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H C PitotH E Windschitl
Mar 21, 1998·Science·L StewartJ J Champoux
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V M HerbenW W ten Bokkel Huinink
Nov 26, 1999·Molecular Pharmacology·H M Dodds, L P Rivory
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H TakimotoJ L Grem
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJ Randolph Hecht

❮ Previous
Next ❯

Citations

Jan 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars M WagnerKatherine K Matthay
Jun 16, 2007·Pediatric Blood & Cancer·Lars M WagnerWayne L Furman
Jul 10, 2010·Anti-cancer Drugs·Linda J M OostendorpPetronella B Ottevanger
Jul 16, 2010·British Journal of Cancer·M CosimelliUNKNOWN Italian Society of Locoregional Therapies in Oncology (SITILO)
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Shousong CaoMarwan Fakih
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guy A van HazelJacob George
Mar 23, 2012·Radiology·João Paulo da Silveira Nogueira LimaLucas Vieira dos Santos
Oct 19, 2005·Journal of Biomedical Optics·D RohlederW Petrich
Jan 28, 2017·The Cochrane Database of Systematic Reviews·Simone MocellinXavier Bonfill Cosp
Jul 26, 2016·Molecular and Clinical Oncology·Yi ShaoDian-Sheng Zhong
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephan A VeltkampJan H M Schellens
May 10, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amanda TownsendTimothy Price
Jun 6, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines
Nov 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
deacylation

Software Mentioned

NONMEM
SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.